AMPH: Amphastar Company Value to Net Income

Corporate emblem and logo of Amphastar Pharmaceuticals Inc (AMPH)

The historical P/E chart for Amphastar Pharmaceuticals (AMPH) demonstrates earnings valuation dynamics, where 12.50 becomes the new value for this metric. Glucagon sales and the integration of Baqsimi support the growth in market capitalization. Brand stability is based on the quality of complex injectable systems. Nasal glucagon and generics provide the current effect while the market awaits approval of new inhalation lines.

AMPH Amphastar Corp: Price to Earnings Ratio in the range 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Amphastar (AMPH)

- price and consensus price forecast:
Stock Price amphastar.com|AMPH - Consensus Target
- market capitalization information:
Market Value Amphastar Pharmaceuticals, Inc.|AMPH - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Amphastar Pharmaceuticals|AMPH - Company Net Assets|Market Cap to Book Value Multiple amphastar.com|AMPH - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Amphastar Pharmaceuticals|AMPH - Long-Term Debt to Capital|Current Liabilities to Capital Amphastar Corp|AMPH - Company Debts|Debt to Net Assets Ratio Amphastar Pharmaceuticals, Inc.|AMPH - Company Long-Term Debts|Company Short-Term Debts Amphastar Pharmaceuticals|Quick Liquidity Indicator amphastar.com
- business earnings and investment ratios data:
AMPH - Company Net Income|Forward Earnings Amphastar Pharmaceuticals|AMPH - P/E Multiple|Future Price to Earnings Multiple Amphastar Pharmaceuticals Inc|AMPH - PEG Multiple|EV/EBITDA Multiple Amphastar Pharmaceuticals, Inc.|AMPH - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Amphastar Pharmaceuticals|AMPH - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months amphastar.com|AMPH - Earnings growth in current year|Earnings growth forecast for next year Amphastar Pharmaceuticals
- issuer revenue and sales details:
AMPH - Company Revenue|Company Future Revenue amphastar.com|AMPH - Market Cap to Revenue|Forward Price to Sales Amphastar Pharmaceuticals, Inc.
Comprehensive company analysis:amphastar.com - AMPH
Flagship merchandise of Amphastar Pharmaceuticals, Inc.

Sales of flagship drugs and the launch of high-margin generics by Amphastar Pharmaceuticals (AMPH) directly determine net income, which serves as the denominator when calculating the stock's market value. By analyzing the issuer's P/E ratio, an investor assesses the payback period for investments through the lens of current earnings, where extreme values on the chart signal either overvalued assets or hidden structural business risks.

Key competitors

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|PCRX (pacira.com) - Company Value to Net Income|P/E Multiple SPRY (ARS Pharmaceuticals, Inc.)|P/E Multiple Theravance Biopharma Inc TBPH|AQST - Price to Earnings Ratio|scPharmaceuticals Inc. (SCPH) - Price to Earnings Ratio|tectonictx.com (TECX) - Price to Earnings Ratio|Market Cap to Net Income TNXP (tonixpharma.com)|SXTC (SXT Pharmaceuticals) - P/E Multiple|EPRX: Company Value to Net Income|P/E Multiple BHST|P/E Multiple Invizyne (EXOZ)|Price to Earnings Ratio Oramed Pharmaceuticals Inc. ORMP|Business Payback Period Entera Bio Ltd (ENTX)|HYFT: Price to Earnings Ratio|ABVC BioPharma Inc. - Market Price to Net Income Ratio|CPIX: P/E Multiple|Quantum BioPharma Corp (QNTM) - P/E Multiple|Price to Earnings Ratio FibroGen, Inc.|TELO: Company Value to Net Income|Price to Earnings Ratio RANI (Rani Therapeutics)|SNYR (synergychc.com) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|LEXX (Lexaria Bioscience Corp) - Market Cap to Net Income|Pulmatrix, Inc. - P/E Multiple|Company Value to Net Income PTHL (Pheton Holdings Ltd)|APM: P/E Multiple|Lyra Therapeutics Inc. (LYRA) - P/E Multiple|Price to Earnings Ratio Impact BioMedical|TNFA: Company Value to Net Income|Price to Earnings Ratio cbdMD, Inc. (YCBD)|Price to Earnings Ratio painreform.com PRFX|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|P/E Multiple Lipella Pharmaceuticals Inc LIPO|Optinose - P/E Multiple|Pieris Pharma (PIRS) - Price to Earnings Ratio|PROC: P/E Multiple|Market Cap to Earnings petrospharma.com (PTPI)|Price to Earnings Ratio QLI|P/E Multiple Acelyrin Inc.|Price to Earnings Ratio TFFP (TFF Pharma)